Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Loken

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Cancer|August 24, 2005
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrenceRichard A Larson, Eric L Sievers, Edward A Stadtmauer, et al.
Blood|May 5, 2021
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology GroupKatherine Tarlock, Adam J Lamble, Yi-Cheng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2005
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemiaMohamed L Sorror, Michael B Maris, Brenda M Sandmaier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2025
Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology GroupBenjamin J Huang, Lauren K Meyer, Todd A Alonzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2025
Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology GroupBenjamin J Huang, Lauren K Meyer, Todd A Alonzo, et al.
Blood Advances|October 22, 2025
Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual DiseaseJason N Berman, Anupam Verma, Shelton A Viola, et al.
Blood Advances|May 3, 2021
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemiaAllison J Kaeding, Sonali P Barwe, Anilkumar Gopalakrishnapillai, et al.
Haematologica|February 1, 2024
CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology GroupAndrew J Menssen, Chad A Hudson, Todd Alonzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2019
Comprehensive Transcriptome Profiling of Cryptic <i>CBFA2T3-GLIS2</i> Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML StudyJenny L Smith, Rhonda E Ries, Tiffany Hylkema, et al.
Leukemia|October 4, 2024
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment responseMeagan A Jacoby, Eric D Duncavage, Ajay Khanna, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Cancer|August 24, 2005
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrenceRichard A Larson, Eric L Sievers, Edward A Stadtmauer, et al.
Blood|May 5, 2021
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology GroupKatherine Tarlock, Adam J Lamble, Yi-Cheng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2005
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemiaMohamed L Sorror, Michael B Maris, Brenda M Sandmaier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2025
Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology GroupBenjamin J Huang, Lauren K Meyer, Todd A Alonzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2025
Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology GroupBenjamin J Huang, Lauren K Meyer, Todd A Alonzo, et al.
Blood Advances|October 22, 2025
Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual DiseaseJason N Berman, Anupam Verma, Shelton A Viola, et al.
Blood Advances|May 3, 2021
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemiaAllison J Kaeding, Sonali P Barwe, Anilkumar Gopalakrishnapillai, et al.
Haematologica|February 1, 2024
CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology GroupAndrew J Menssen, Chad A Hudson, Todd Alonzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2019
Comprehensive Transcriptome Profiling of Cryptic <i>CBFA2T3-GLIS2</i> Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML StudyJenny L Smith, Rhonda E Ries, Tiffany Hylkema, et al.
Leukemia|October 4, 2024
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment responseMeagan A Jacoby, Eric D Duncavage, Ajay Khanna, et al.
Pageof 10